1 Undervalued TSX Stock Down 12% to Buy and Hold
Written by Amy Legate-Wolfe at The Motley Fool Canada
Investors are always on the lookout for undervalued stocks on the TSX, especially during times of market uncertainty. These are companies that have fallen out of favour in the short term but still offer strong fundamentals, long-term growth, and dependable income. One such stock is Magna International (TSX:MG). It's down roughly 12% over the past year, yet it remains one of the most stable and promising manufacturing names on the Canadian market. For those looking to buy and hold, this could be a smart time to take a closer look.
Magna is a global leader in automotive parts. It supplies components to nearly every major automaker, including systems for powertrains, seating, electronics, and body exteriors. As electric vehicles (EVs) gain more ground, Magna has made the shift to support EV development as well, keeping it aligned with industry trends. Its scale, global reach, and ability to adapt have helped it maintain a solid position even through the ups and downs of the auto market.
In the first quarter of 2025, Magna reported a net income of US$146 million, which marked a strong rebound from earlier quarters impacted by labour disruptions and cost pressures. Revenue came in at US$10.97 billion, up from US$10.67 billion the year before. The dividend stock also raised its sales guidance for the year, reflecting optimism about order flows and production volume in the second half of 2025.
What really makes Magna stand out right now is its valuation. It trades at a forward price-to-earnings (P/E) ratio of about 7.8 and a trailing P/E of 9.1. For context, many TSX-listed industrial stocks trade well above those levels. Investors often look at single-digit P/E ratios as a sign of undervaluation, especially when the underlying business remains profitable and forward-looking. Magna also trades at just 0.85 times book value and under seven times free cash flow, making it one of the more affordable large-cap manufacturing names in Canada.
At the time of writing, the dividend stock trades around $52.66, down from the mid-$60s earlier in the year. That's a decline of nearly 12%, much of it linked to broader concerns about interest rates, supply chain issues, and tariff fears. However, the dividend stock hasn't fallen because of company-specific problems. It's still growing earnings, generating strong cash flow, and maintaining healthy relationships with automakers globally.
Then there's the dividend. Magna currently pays $2.68 per share annually for a yield of just under 5%. The dividend stock increased its dividend for 12 straight years, showing a commitment to shareholders. The current payout ratio is around 47%, leaving room for continued increases if earnings improve. In a volatile market, a reliable dividend goes a long way in providing investors with income and stability while they wait for a rebound. Meanwhile, a $5,000 investment could bring in $251.92 per year!
COMPANY
RECENT PRICE
NUMBER OF SHARES
DIVIDEND
TOTAL PAYOUT
FREQUENCY
TOTAL INVESTMENT
MG
$52.66
94
$2.68
$251.92
Quarterly
$4,951.96
Magna is also financially sound. It produced nearly $5 billion in operating cash flow over the last year and has about $2.15 billion in free cash flow. While it carries about $10.86 billion in debt, it maintains strong coverage ratios and continues to invest in future growth, including technologies supporting electric and autonomous vehicles.
Because it operates globally, Magna is not overly reliant on one market. In fact, 46% of sales come from North America and 43% from Europe. This spread helps smooth out the effects of regional slowdowns or economic hiccups. With production expected to ramp up in the second half of the year and inflation pressures easing, the timing may be right for a longer-term recovery in the auto sector.
In the end, Magna is a dividend stock that checks a lot of boxes. It's undervalued, down about 12% over the past year, and still paying out a strong dividend. It has global reach, reliable earnings, and the kind of financial discipline that gives investors confidence. For anyone looking to buy and hold a TSX stock with both income and growth potential, Magna International might just be the right fit.
The post 1 Undervalued TSX Stock Down 12% to Buy and Hold appeared first on The Motley Fool Canada.
More reading
Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS]
Market Volatility Toolkit
Best Canadian Stocks to Buy in 2025
Beginner Investors: 4 Top Canadian Stocks to Buy for 2025
5 Years From Now, You'll Probably Wish You Grabbed These Stocks
Subscribe to Motley Fool Canada on YouTube
Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool recommends Magna International. The Motley Fool has a disclosure policy.
2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Renault's CEO search may include insider Le Vot, Stellantis' Picat, analysts say
By Nick Carey and Gilles Guillaume LONDON (Reuters) -Luca de Meo's abrupt departure as Renault CEO has kicked off a search for his successor, with analysts mentioning longtime insider Denis Le Vot and Maxime Picat of rival Stellantis as suitable fits to continue the French automaker's turnaround. Renault shares fell as much as 8% on Monday, their biggest one-day percentage drop since February 2022, as investors worried about the company's future without de Meo at the helm. Shares in Kering, where he will become CEO, rallied. Picat, who is head of global purchasing and supply chains at Stellantis, had been in the running for the chief executive officer post at the world's No. 4 automaker. One of two internal candidates, he lost out to Antonio Filosa. Executive vice president Le Vot joined Renault from university and has run its low-cost Dacia brand since May 2022. Analysts at French brokerage Kepler Cheuvreux said both men could be potential successors, whilst JP Morgan analyst Jose Asumendi noted Renault's "strong bench" of brand managers, including at Dacia. "We (...) also would envision potential external candidates from (other companies) such as Stellantis, VW Group, Nissan, amongst other competitors," he said. Le Vot and Picat, who are both French nationals, did not immediately respond to requests for comment. Renault declined to comment on its succession plans. Whoever succeeds de Meo will have to hit the ground running. Although he revived Renault and overhauled its strategic alliance with Nissan during his five years as CEO, like other traditional automakers it faces rising competition from Chinese rivals. The company must also lean on partnerships because it is smaller than most other mainstream manufacturers. De Meo's departure will add to concerns about Renault's ability to remain independent, said Jefferies analysts, a perennial challenge in an industry built on scale. Renault was the world's No. 15 automaker by sales in 2024, according to data compiled by industry analyst Felipe Munoz, down from 14th spot in 2023. In recent years, it has been overtaken by Chinese automakers BYD, Geely, Chery and Changan is likely to surpass it in sales this year. To make up for its small size as the auto industry wrestles with the huge expense of going electric, Renault under de Meo teamed up with a number of partners and investors including Google, Qualcomm and China's Geely. The partnerships have helped reduce costs, but labour unions claim they threaten the company's in-house know-how. INSIDER VS OUTSIDER Under Le Vot's leadership, the Dacia brand has performed well thanks to its Sandero and Duster models. In April, the subcompact Sandero was Europe's No. 2 selling car - behind the Renault Clio - and the Duster SUV was No. 7, according to research firm JATO Dynamics. Le Vot had previous management stints in Turkey and Russia, where he was chief operating officer from 2011 to 2013, and ran North American operations at alliance partner Nissan, where he oversaw the launch of the new Altima sedan in 2018. Picat has spent his entire career at PSA and then Stellantis, formed when the French group merged with FCA in 2021. He was head of the Peugeot brand from 2012, where he oversaw the launch of two of its bestsellers, the 2008 and 3008 SUVs. A Stellantis source who knows Picat said he didn't know if he was interested in the top job at Renault, but that he would "not be surprised" if he was talking to the French automaker. The source, who spoke on condition of anonymity because he was not authorised to discuss the matter publicly, said it would be normal for an executive to look elsewhere after losing the race to become CEO. (Additional reporting by Giulio Piovaccari in Milan; Editing by Josephine Mason and Catherine Evans)
Yahoo
an hour ago
- Yahoo
Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6
The new full visual range*1 IOL enables 93% of patients to become free from glasses at all distances.**2 *** With best-in-class image contrast and low-light performance,#~3,4,5 TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs. TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15 This content is intended for Healthcare Professionals only, not for the general public. JACKSONVILLE, Fla., June 17, 2025 /CNW/ -- Johnson & Johnson,§ a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC - IOL) with the roll-out of TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The new full visual range*1 IOL offers high-quality and continuous vision with unmatched range.$6,16 This will allow patients to see clearly from far to near and in between, minimizing their need for glasses.‡+2,6,7 Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision. "TECNIS Odyssey IOL is the fastest growing PC-IOL in the United States,^ and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence.+ Now – together with TECNIS PureSee – TECNIS Odyssey IOL elevates the strength and depth of our global IOL portfolio, meeting the diverse needs of today's aging population," said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. Currently, an estimated 94 million people aged 50 years and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery.8 These figures are projected to increase, since presbyopia and cataract development are part of the aging process. Presbyopia is a progressive eye condition that makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age.9 Full visual range IOLs provide the opportunity to correct presbyopia at the time of lens replacement surgery. "From my early experience, what sets the TECNIS Odyssey IOL apart, is its ability to deliver consistent visual outcomes across a wide range of patients, due to its advanced design with higher tolerance to residual refractive error,"∫7,11 said Professor Beatrice Cochener-Lamard, Head of the Ophthalmology Department at Brest University Hospital in France.^^^ TECNIS Odyssey IOL is the latest innovation for those seeking greater visual freedom – offering: Precise vision: TECNIS Odyssey IOL provides crisp and clear vision, allowing patients to see with clarity at every distance6 - whether they are reading, driving or engaging in daily activities. 94% of patients were satisfied with their overall vision without glasses.&****12 At every distance: Its unique, freeform diffractive surface was designed to eliminate the gaps between near, intermediate and far distances, and offer continuous, uninterrupted vision at all distances.†‡6 96% of patients were satisfied with reading a smartphone or tablet,&****13 and 97% were satisfied with distance vision.&****12 In any lighting: Engineered to minimize night vision disturbances – fewer halos and glare#14 – TECNIS Odyssey IOL provides better image quality than PanOptix day and night,##3,4,5 for a more comfortable night-time experience. 92% of patients were satisfied with their ability to see steps and read street signs at night.&****13 With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. The Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs available in Europe, the Middle East, Canada, and Japan now includes both TECNIS Odyssey IOL and TECNIS PureSee IOL. TECNIS Odyssey IOL, the full range of vision IOL, is also available in the US, Puerto Rico, and Japan. TECNIS PureSee IOL, the purely refractive, extended depth of focus IOL, is also available across APAC and Latin America. TECNIS PureSee has not received PMA Approval in the U.S. For more patient information and tools please visit Visit us at and and follow Johnson & Johnson | Vision on LinkedIn. About Vision at Johnson & JohnsonJohnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Surgical Vision, Inc. is part of Johnson & Johnson. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of TECNIS Odyssey™ intraocular lens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Footnotes*According to ISO 11979-7:2024, based on the clinical study of the parent IOL **(n=82) 1 month results. Q: "Was the patient wearing any spectacles or contact lenses since the surgery?" Six subjects 6/82 (5 subjects for near, 1 subject for both distance and near); ***Based on 1-month postoperative data from a multicenter, retrospective, real-world clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=96).****Based on 3-month postoperative data from a multicenter, observational clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=33). ¶based on pre-clinical bench testing. The third-party trademarks used herein are the trademarks of their respective owners. ∫compared to TECNIS Synergy™ and TECNIS™ Multifocal IOLs based on pre-clinical bench testing #compared to PanOptix® based on pre-clinical bench testing ##compared to leading competitor full visual range IOLs based on pre-clinical bench testing (white light MTF at 50 c/mm measured for 3mm & 5mm pupil in the ACE model) §Johnson & Johnson represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both. †continuous 20/25 or better ‡based on pre-clinical bench testing ^based on Market Scope's estimated procedure for 2024 vs 2023 ^^^Professor Beatrice Cochener-Lamard is a paid consultant of Johnson & Johnson MedTech ~Compared to TECNIS SYNERGY™ based on bench testing +Individual results will vary. Some TECNIS Odyssey™ IOL patients may require spectacles post-surgery. -Results may vary. Consult your doctor to determine the lens options that are right for you. $Compared to PanOptix® based on bench testing and head-to-head clinical studies of parent lens &Values rounded to the nearest 1% Indication and safety information in regions where these products are available for use is included below. Please note indications may differ based on region. Full safety information is available hyperlinked below. IN THE UNITED KINGDOM The promoted product is a medical device. For healthcare professionals only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question. IN CANADA INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT100, DRT150, DRT225, DRT300, DRT375, IN CANADA: Rx Only INDICATIONS FOR USE: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL which is indicated for primary implantation for the visual correction of aphakia in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs which are indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing vision far through near and reduced spectacle dependence across a range of distances. The lens is intended to be placed in the capsular bag. WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of the possibility of visual effects (such as halo or glare), in nighttime or poor visibility conditions. Patients may perceive these visual effects as an annoyance or hindrance, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of potential spectacle independence. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. Care should be taken to achieve centration of the toric IOL. Safety and effectiveness in patients 21 years or younger have not been established in clinical studies. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS PURESEE™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, AND TECNIS PURESEE™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM IN CANADA INDICATIONS FOR USE The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ IOL which is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, and decreased spectacle dependence. The lens is intended for capsular bag placement only. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ Toric II IOL which is indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, a reduction of residual refractive cylinder, and decreased spectacle dependence. The lens is intended for capsular bag placement only. WARNING Physicians should weigh the potential risk/benefit ratio of IOL implantation in patients with any of the conditions described in the Directions for Use. These conditions are not specific to the design of the IOL and are attributed to cataract surgery and/or IOL implantation in general. The IOL should be placed entirely in the capsular bag. Do not place the IOL in the ciliary sulcus. Patients should be informed of the possibility of visual disturbances. The lens may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL; fully inform the patient of this risk before implanting the lens. Special consideration should be made for patients with macular disease, amblyopia, corneal irregularities, or other ocular disease. Inform patients to exercise special caution when driving at night or in poor visibility conditions. Rotation of the TECNIS PureSee™ Toric II IOL away from their intended axis can reduce their astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, IOL repositioning should occur as early as possible prior to lens encapsulation. Do not attempt to disassemble, modify, or alter the delivery system, or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not use if the cartridge tip is cracked or split. Do not implant the IOL if the rod tip does not advance the IOL or if it is jammed in the delivery system. Do not advance the IOL from the Holding Position (located at the half turn rotation position for the initial advancement of the IOL into the cartridge) prior to fully hydrating the system and ready for implantation. A minimum of 1 minute at the Holding Position is required to fully hydrate the system to prevent sticking and a potential scratch or crack to the IOL. Interruptions during delivery may result in the IOL being scratched or cracked or stuck in the cartridge. Discard the device if the IOL has been advanced past the Holding Position but not delivered within 60 seconds. The IOL and delivery system should be discarded if the IOL has been folded within the cartridge for more than 10 minutes. Not doing so may result in the IOL being stuck in the cartridge. PRECAUTIONS Autorefractors may not provide optimal postoperative refraction of patients with the IOL. Manual refraction with maximum plus technique is strongly recommended. Recent contact lens usage may affect the patient's refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Target emmetropia for optimum visual performance. For the TECNIS PureSee™ Toric II IOL, variability in any preoperative surgical parameters (e.g., keratometric cylinder, incision location, estimated surgically induced astigmatism, or biometry) can influence patient outcomes. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case, to avoid lens rotation. This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. ADVERSE EVENTS Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, persistent cystoid macular edema, persistent corneal stromal edema, persistent raised intraocular pressure (IOP) requiring treatment, secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explanation. ATTENTION Reference the Directions for Use for a complete listing of Indications and Important Safety Information. IN THE UNITED STATES INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT150, DRT225, DRT300, DRT375 IN THE UNITED STATES Rx Only INDICATIONS: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information found here: -------------------------------------------------1 Data on File. 2024DOF4002 (prospective, multicenter, randomized, three-way-masked clinical study comparing subjectsbilaterally implanted with TECNIS Synergy IOL (n=132) vs TECNIS 1-Piece Monofocal IOL (n=131) at 6-months post-op) 2 Data on File. DOF2023CT4051. 3 Data on File. 2024DOF4033 4 Data on File. DOF2019OTH4002 5 Data on File. DOF2023CT4007 6 Data on File. DOF2023CT4023 7 Data on File. 2024DOF4003 8 World report on vision. Geneva: World Health Organization, 2019. Available at: Last accessed: May 2025. 9 What Is Presbyopia – American Academy of Ophthalmology. Access from: 2024REF5075. 11 Data on File. 2024DOF4017 12 Data on File. 2024DOF4027. 13 Data on File. 2024DOF4029. 14 Data on File. 2024DOF4005 15 DOF2023CT4052 16 DOF2020CT4014 Media contact (EMEA): Sarah Smithssmith49@ Media contact (NA): Maggie Lorenzmloren15@ Investor contact:Sandra Eastoninvestor-relations@ View original content to download multimedia: SOURCE Johnson & Johnson Medical Devices Companies View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Amazon announces four-day Prime Day discount event
By Arriana McLymore NEW YORK (Reuters) - annual Prime Day sales event is scheduled for July 8 through July 11, expanding to four days from two days compared to last year, the company announced on Tuesday. "We're extending it to four days because our members have told us they just need more time to shop the deals," Jamil Ghani, Amazon vice president of worldwide prime, told Reuters. Amazon's expanding Prime Day comes as U.S. shoppers and retailers face uncertainty on how tariffs will impact prices and product availability, said Rob Garf, senior vice president of strategy and insights at retail marketing firm Cordial. U.S. shoppers spent $14.2 billion, up 11% year-over-year, during Amazon's July 2024 Prime Day event, according to Adobe Analytics. The e-commerce giant often faces competing sales events from Walmart, Target and, now, ByteDance's TikTok Shop, which are trying to lure shoppers into spending early on back-to-school and back-to-college merchandise including personal electronics, apparel and home goods. The online retailer wants to entice younger shoppers to sign up for its subscription service Prime, by offering discounted memberships for people between the ages of 18 and 24 and other perks. Prime subscriptions typically cost $14.99 per month or $139 per year. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
